Vapiprost

Drug Profile

Vapiprost

Alternative Names: GR 32191; GR 32191B; SN 309

Latest Information Update: 17 Jan 2008

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; GlaxoSmithKline KK
  • Class Antiplatelets
  • Mechanism of Action Thromboxane receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Asthma; Coronary artery restenosis; Deep vein thrombosis; Ischaemic heart disorders

Most Recent Events

  • 01 Sep 1999 No-Development-Reported for Coronary artery restenosis in Japan (Unknown route)
  • 01 Sep 1999 No-Development-Reported for Deep vein thrombosis in Japan (Unknown route)
  • 21 Aug 1996 A study has been added to the Ischaemic Heart Disease and Thromboses therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top